Distinguished in Retinopathy of Prematurity

Dr. Cagri G. Besirli

Ophthalmology
Regents Of The University Of Michigan
1000 Wall St, 
Ann Arbor, MI 
Accepting New Patients
Distinguished in Retinopathy of Prematurity
Regents Of The University Of Michigan
1000 Wall St, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Cagri Besirli is an Ophthalmologist in Ann Arbor, Michigan. Dr. Besirli is rated as a Distinguished provider by MediFind in the treatment of Retinopathy of Prematurity. His top areas of expertise are Retinal Detachment, Late-Onset Retinal Degeneration, Stickler Syndrome, Vitrectomy, and Trabeculectomy. Dr. Besirli is currently accepting new patients.

His clinical research consists of co-authoring 132 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Retinopathy of Prematurity.

Specialties
Ophthalmology
Licenses
Ophthalmology in MI
Hospital Affiliations
University Of Michigan Health System
Languages Spoken
English
Turkish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF MICHIGAN
1000 Wall St, Ann Arbor, MI 48105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Biological
Study Drug: Either AAV - CNGB3 or AAV - CNGA3
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Biological, Other
Study Drug: 4D-125
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Biological
Study Drug: rAAV2tYF-CB-hRS1
Study Phase: Phase 1/Phase 2
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3
Enrollment Status: Completed
Publish Date: December 01, 2022
Intervention Type: Biological
Study Drug: AAV- CNGA3
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

132 Total Publications

Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium.
Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium.
Journal: Translational vision science & technology
Published: August 27, 2025
Similar Doctors
Elite in Retinopathy of Prematurity
Dr. Antonio Capone
Ophthalmology
Elite in Retinopathy of Prematurity
Dr. Antonio Capone
Ophthalmology

Associated Retinal Consultants PC

3555 W 13 Mile Rd, 
Royal Oak, MI 
 (32.0 miles away)
248-288-2280
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients

Antonio Capone is an Ophthalmologist in Royal Oak, Michigan. Dr. Capone is rated as an Elite provider by MediFind in the treatment of Retinopathy of Prematurity. His top areas of expertise are Norrie Disease, Familial Exudative Vitreoretinopathy, Retinal Detachment, Coats Disease, and Vitrectomy. Dr. Capone is currently accepting new patients.

Distinguished in Retinopathy of Prematurity
Dr. Nita G. Valikodath
Ophthalmology
Distinguished in Retinopathy of Prematurity
Dr. Nita G. Valikodath
Ophthalmology

Regents Of The University Of Michigan

1000 Wall St, 
Ann Arbor, MI 
 (0.1 miles away)
734-764-4190
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nita Valikodath is an Ophthalmologist in Ann Arbor, Michigan. Dr. Valikodath is rated as an Advanced provider by MediFind in the treatment of Retinopathy of Prematurity. Her top areas of expertise are Retinopathy of Prematurity, Retinal Detachment, Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy. Dr. Valikodath is currently accepting new patients.

Advanced in Retinopathy of Prematurity
Dr. Xihui N. Lin
Ophthalmology
Advanced in Retinopathy of Prematurity
Dr. Xihui N. Lin
Ophthalmology

University Physician Group

4717 Saint Antoine St, 
Detroit, MI 
 (35.1 miles away)
313-577-8900
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Xihui Lin is an Ophthalmologist in Detroit, Michigan. Dr. Lin is rated as a Distinguished provider by MediFind in the treatment of Retinopathy of Prematurity. His top areas of expertise are Gyrate Atrophy of the Choroid and Retina, Endophthalmitis, Diabetic Retinopathy, Vitrectomy, and Cataract Removal. Dr. Lin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Besirli's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 22 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile